Using Immuno-Oncological Biomarker-Directed Strategies as a Blueprint For Developing Effective Treatments for Alzheimer’s Disease
CJ Barnum,
Director of Neuroscience,
INmune Bio, Inc.
INmune Bio approaches Alzheimer’s disease (AD) as an immunological disease, not a neurological disease. This changes the clinical strategy in many ways but perhaps none more important than we now have biomarkers. We have developed a suite of biomarkers that extend beyond classical blood inflammatory measures that will inform go/no decisions.
|
|
